Systematic Review

Optimal Anticoagulant Strategy for Periprocedural Management of Atrial Fibrillation Ablation: A Systematic Review and Network Meta-Analysis

Tabito Kino 1, Minako Kagimoto 2, Takayuki Yamada 3, Satoshi Ishii 2, Masanari Asai 4, Shunichi Asano 5, Hideto Yano 6, Toshiyuki Ishikawa 7 and Tomoaki Ishigami 7,*

1 Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA; tabito.kino@temple.edu
2 Department of Cardiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama 236-0051, Japan; minako.kagimoto@gmail.com (M.K.); e103004g@yokohama-cu.ac.jp (S.I.)
3 Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA; yamadat@upmc.edu
4 Department of Cardiology, Saiseikai Yokohamashi Nanbu Hospital, Yokohama 234-0054, Japan; masanari@yokohama-cu.ac.jp
5 Department of Cardiology, Yokohama Rosai Hospital, Yokohama 222-0036, Japan; shunasncirc@gmail.com
6 Department of Cardiology, Gyotoku General Hospital, Ichikawa 272-0103, Japan; yanoht@uno.dti.ne.jp
7 Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan; tishika@yokohama-cu.ac.jp
*
Correspondence: tommmish@hotmail.com; Tel.: +81-45-787-2635

Abstract: This network meta-analysis was performed to rank the safety and efficacy of periprocedural anticoagulant strategies in patients undergoing atrial fibrillation ablation. MEDLINE, EMBASE, CENTRAL, and Web of Science were searched to identify randomized controlled trials comparing anticoagulant regimens in patients undergoing atrial fibrillation ablation up to July 1, 2021. The primary efficacy and safety outcomes were thromboembolic and major bleeding events, respectively, and the net clinical benefit was investigated as the primary-outcome composite. Seventeen studies were included (n = 6950). The mean age ranged from 59 to 70 years; 74% of patients were men and 55% had paroxysmal atrial fibrillation. Compared with the uninterrupted vitamin-K antagonist strategy, the odds ratios for the composite of primary safety and efficacy outcomes were 0.61 (95%CI: 0.31–1.17) with uninterrupted direct oral anticoagulants, 0.63 (95%CI: 0.26–1.54) with interrupted direct oral anticoagulants, and 8.02 (95%CI: 2.35–27.45) with interrupted vitamin-K antagonists. Uninterrupted dabigatran significantly reduced the risk of the composite of primary safety and efficacy outcomes (odds ratio, 0.21; 95%CI, 0.08–0.55). Uninterrupted direct oral anticoagulants are preferred alternatives to uninterrupted vitamin-K antagonists. Interrupted direct oral anticoagulants may be feasible as alternatives. Our results support the use of uninterrupted direct oral anticoagulants as the optimal periprocedural anticoagulant strategy for patients undergoing atrial fibrillation ablation.

Keywords: periprocedural anticoagulant management; atrial fibrillation ablation; direct oral anticoagulant; vitamin-K antagonist; network meta-analysis

1. Introduction

Atrial fibrillation (AF) is a cardiac arrhythmia common worldwide [1]. Catheter ablation (CA) is the most effective treatment to prevent AF recurrence [2], and over the last decade, it has resulted in dramatic improvements in safety and efficacy [3–7]. However, periprocedural complications occur in approximately 4–14% of patients undergoing AF ablation, 2–3% of which are potentially life-threatening [8]. Periprocedural stroke or transient ischemic attack (TIA) and cardiac tamponade are the most notable complications [9,10]. As these adverse events are affected by periprocedural anticoagulant management, an
optimal anticoagulant strategy is essential for the prevention of thromboembolic and bleeding complications.

Compared with vitamin-K antagonists (VKAs), direct oral anticoagulants (DOACs) have been shown to have a favorable risk-benefit profile, as they significantly reduce the incidence of stroke and also carry a similar bleeding risk in the long-term treatment of patients with AF [11]. With respect to CA, many studies have found that DOACs have similar efficacy and safety compared with VKAs [12–19]. These results led to the guideline recommendation of uninterrupted anticoagulants for the perioperative management of patients undergoing AF ablation [8,9]. Conversely, a German survey reported that interrupted and minimally interrupted DOAC was used more frequently than truly uninterrupted DOAC to avoid bleeding complications [20]. Moreover, some meta-analyses including randomized controlled trials (RCTs) have revealed that interrupted DOAC was not inferior to uninterrupted DOAC administration and was preferable to uninterrupted VKA administration [21,22]. Currently, guidelines lack indications based on these RCTs regarding which strategy is preferable for periprocedural anticoagulant management. This was the first study comparing each strategy and regimen with network meta-analysis (NMA) to simultaneously compare multiple treatments in a single analysis by combining direct and indirect evidence within a network of RCTs [23].

This study aimed to synthesize the available evidence from RCTs using NMA to: (1) assess the relative effects of different uninterrupted or interrupted anticoagulant strategies between DOACs and VKAs for reducing thromboembolic or bleeding events in patients undergoing AF ablation; and (2) to rank regimens, uninterrupted or interrupted, and DOAC or VKA administration for effectiveness in preventing thromboembolic or bleeding complications.

2. Materials and Methods
2.1. Protocol and Registration

Our report follows the preferred reporting items for systematic reviews and meta-analyses (PRISMA)-NMA extension (Table S1) [24]. The study protocol was registered at PROSPERO (CRD42021268787).

2.2. Eligibility Criteria

Only studies that met the eligibility criteria were included. The criteria were: (1) only RCTs; (2) uninterrupted or interrupted anticoagulant strategy in the periprocedural period; (3) patients undergoing AF ablation; and (4) publication of efficacy (stroke, TIA, or systemic embolism) and safety (major bleeding) outcomes. We excluded duplicate studies. There were no language or publication date restrictions.

2.3. Search Strategy

We performed a systematic search of the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science databases up to July 1, 2021. The search used the Population, Intervention, Comparators, Outcomes, and Study design format and included the following terms: atrial fibrillation, ablation, periprocedural anticoagulation, and randomized controlled trial (Table S2). Three independent and blinded reviewers (SI, MA, and SA) separately assessed the search results to select studies based on the eligibility criteria. When a consensus was not reached by the three reviewers, a fourth author (TI) was consulted to reach a decision.

2.4. Outcomes

The primary efficacy outcome was thromboembolic events, including stroke, TIA, or systemic embolism. The primary safety outcome was major bleeding as defined by the Bleeding Academic Research Consortium (BARC) [25] or the International Society on Thrombosis and Hemostasis (ISTH) [26]. The secondary safety outcome was minor bleeding, and the secondary efficacy outcome was asymptomatic cerebral embolism (ACE).
ACE was diagnosed using diffusion-weighted magnetic resonance imaging (MRI). Minor bleeding was defined as any bleeding that did not fulfill the BARC or ISTH criteria. The net clinical benefit was investigated as a composite of the primary safety and efficacy outcomes.

2.5. Data Extraction and Synthesis

We extracted the following data from the studies: study name, baseline characteristics, anticoagulant regimens, and outcomes. Two reviewers (MK and TY) independently extracted the data. When disagreements between reviewers occurred, a third author (TI) was consulted to reach a decision.

All study regimens were synthesized as follows: uninterrupted DOAC (UI-DOAC), interrupted DOAC (I-DOAC), uninterrupted VKA (UI-VKA), and interrupted VKA (I-VKA) administration. The number of thromboembolic events, major bleeding, composite of primary outcomes, minor bleeding, and ACE were synthesized, and odds ratios (ORs) were estimated. Additionally, all strategies were synthesized per anticoagulant (apixaban, dabigatran, edoxaban, rivaroxaban, and warfarin), and the ORs of the composite of the primary outcomes were estimated in subgroup analyses. The geometry of the network was illustrated using direct comparative treatments.

2.6. Risk of Bias Assessment

We evaluated the risk of bias using the revised Cochrane risk-of-bias tool for randomized trials (RoB2) [27]. Two reviewers (MK and TY) were involved in the quality assessment; if disagreements occurred, a third author (TI) was consulted to reach a consensus.

2.7. Statistical Analysis

NMA statistical analyses were performed with frequentist methods using Netmeta (version 1.5-0) in R 4.1.0 (R Foundation for Statistical Computing, Vienna, Austria). The ORs and 95% confidence intervals (CIs) were estimated based on a random effects model. Additionally, we calculated the P-score and the surface under the cumulative ranking (SU-CRA) to evaluate and rank the anticoagulant strategies and regimens [28,29]. Both rankings are measured on a scale from 0 (worst) to 1 (best). Common network heterogeneity was evaluated using the $I^2$ measure to locate the source of heterogeneity [30]. Heterogeneity was defined as low, moderate, or high when $I^2$ was 25%, 50%, or 75%, respectively [31]. Inconsistency between direct and indirect evidence was examined globally and locally [32,33]. Begg’s rank correlation and Egger’s linear regression were performed to assess publication bias among the studies [34,35]. We conducted sensitivity analyses by excluding one study at a time for the four different strategies of the network. Subgroup analysis was performed to evaluate each anticoagulant regimen for the composite of the primary outcomes.

3. Results

3.1. Study Identification and Study Population Characteristics

We initially identified 124 studies via the electronic databases, and four additional studies were identified through references. Fifty duplicate studies were removed and 78 were screened. We excluded 57 studies after screening the titles and abstracts, and 21 were retrieved for detailed evaluation, from which four studies were subsequently excluded from the analysis because they did not meet the eligibility criteria (Figure 1). Finally, our meta-analysis included 17 RCTs with 6950 patients undergoing AF ablation [36–52]. They were allocated to I-VKA ($n = 835$) [36,37], UI-VKA ($n = 2097$) [36,38–44], I-DOAC ($n = 1465$) [37,38,45–51], and UI-DOAC ($n = 2553$) groups [39–52]. All approved DOACs (apixaban [40,43,45–51], dabigatran [37,38,41,47,48,51], edoxaban [44,48,49,51,52], and rivaroxaban [39,42,45,47–49,51,52]) were included.
The age of the participants ranged from 59 to 70 years (median = 62 years); 74% were men and 55% had paroxysmal AF. Twelve studies (71%) reported mean CHA₂DS₂-VASc scores ranging from 1.5 to 2.8 (median 2.0). In 15 studies (88%), the median follow-up duration was 30 days (range: 2–90 days). The detailed clinical characteristics of the included studies are summarized in Tables 1 and S3.
| Study                  | Year     | Regimen         | n    | Age (years) | Male Sex | Paroxysmal AF | CHA<sub>2</sub>-VASc | HAS-BLED | Mean ACT | Target ACT | Total UFH Dose | Protamine | ICE | Ablation Technology | Follow-Up Period |
|-----------------------|----------|-----------------|------|-------------|----------|---------------|---------------------|----------|----------|------------|-----------------|------------|-----|---------------------|------------------|
| COMPARE [36]          | 2014     | UI-Warfarin I-Warfarin | 794  | 59          | 59       | 230 (73%)     | 200 (63%)          | 229 (72%) | NR       | >300       | NR             | Used † | NR  | RF                  | 48 h             |
| Nin [37]              | 2013     | I-Dabigatran 110 mg BID I-Warfarin | 45   | 61          | 61       | 38 (84%)      | 34 (76%)           | 32 (71%)   | NR       | NR         | 300–400        | Used † | NR  | RF                  | 14 days          |
| ABRIDGE-J [38]        | 2019     | I-Dabigatran 150/110 mg BID I-Warfarin | 220  | 65          | 66       | 171 (78%)     | 138 (63%)          | 138 (62%)  | 2.0 *    | 1.0 *      | NR             | 300–400   | NR  | RF                  | 3 months         |
| VENTURE-AF [39]       | 2015     | UI-Rivaroxaban 20 mg OD UI-Warfarin | 114  | 59          | 61       | 86 (75%)      | 95 (83%)           | 87 (81%)   | NR       | >300       | 13,871         | 32 (28%) | RF/Cryo | 30 days            | 3 months          |
| Kuwahara [40]         | 2016     | UI-Apixaban 5/2.5 mg BID UI-Warfarin | 100  | 65          | 66       | 75 (75%)      | 59 (59%)           | 60 (60%)   | NR       | >300       | 12,402         | 27 (25%) | RF/Cryo | 30 days            | 3 months          |
| RE-CIRCUIT [41]       | 2017     | UI-Dabigatran 150 mg BID UI-Warfarin | 317  | 59          | 59       | 230 (73%)     | 213 (67%)          | 219 (69%)  | NR       | >300       | 12,002         | 11,910    | RF/Cryo | 56 days            | 90 days           |
| ASCERTAIN [42]        | 2018     | UI-Rivaroxaban 15/10 mg OD UI-Warfarin | 64   | 59          | 62       | 53 (83%)      | 40 (63%)           | 42 (67%)   | NR       | 300–400    | 12,500         | Used † | NR  | RF                  | 30 days          |
| AXAFA-AFNET 5 [43]    | 2018     | UI-Apixaban 5/2.5 mg BID UI-Warfarin | 318  | 64          | 64       | 218 (69%)     | 189 (59%)          | 178 (57%)  | NR       | >300       | 17,800         | 137 (91%) | RF/Cryo | 30 days            | 3 months          |
| ELIMINATE-AF [44]     | 2019     | UI-Edoxaban 60 mg OD UI-Warfarin | 375  | 60          | 61       | 290 (77%)     | 284 (76%)          | 131 (74%)  | NR       | 300–400    | 11,473         | 42 (24%) | RF/Cryo | 90 days            | 30 days          |
| Yoshimura [45]        | 2019     | UI-Rivaroxaban 15/10 mg OD I-Apixaban 5/2.5 mg BID | 55   | 59          | 59       | 45 (82%)      | 33 (60%)           | 31 (62%)   | NR       | >300       | 15,745         | 14,240    | RF  | Unclear             | 30 days          |
| AEIOU [46]            | 2018     | UI-Apixaban 5 mg BID I-Apixaban 5/2.5 mg BID | 150  | 63          | 64       | 101 (67%)     | 100 (67%)          | 91 (63%)   | 2.2       | 1.0         | 17,800         | 19,700    | NR  | RF/Cryo             | 30 days          |
| Nakamura [48]         | 2019     | UI-DOAC (Api/Dab/Riv) UI-DOAC (Api/Dab/Riv) | 421  | 65          | 65       | 298 (71%)     | 222 (53%)          | 236 (58%)  | 2.0       | 1.3         | 12,956         | 405 (96%) | NR  | RF                  | 30 days          |
Table 1. Cont.

| Study            | Year | Regimen                      | n   | Age (years) | Male Sex | Paroxysmal AF | CHA2DS2-VASc | HAS-BLED | Mean ACT | Target ACT | Total UFH Dose | Protamine | ICE          | Ablation Technology | Follow-Up Period |
|------------------|------|------------------------------|-----|-------------|----------|---------------|--------------|-----------|----------|------------|----------------|------------|--------------|---------------------|------------------|
| Nagao [49]       | 2019 | UI-DOAC (Apx/Edo/Riv)       | 100 | 70          | 64 (64%) | 57 (57%)      | 2.8          | NR        | 285      | >300       | 8704          | Used †     | Used †       | RF                  | 1 month          |
|                  |      | UI-DOAC (Apx/Edo/Riv)       | 100 | 70          | 62 (62%) | 59 (59%)      | 2.6          | NR        | 280      | >300       | 9945          | Used †     | Used †       | RF                  |                  |
| Ando [50]        | 2019 | UI-Apixaban 5 mg BID        | 32  | 67          | 26 (81%) | 32 (100%)     | NR           | NR        | 300–350  | NR         | NR           | Used †     | NR           | Cryo                | 30 days          |
|                  |      | I-Apixaban 5 mg BID         | 65  | 66          | 49 (75%) | 65 (100%)     | NR           | NR        | NR       | 300–400    | NR           | Used †     | NR           | RF                  |                  |
| Yamaji [51]      | 2019 | UI-DOAC (Apx/Dab/Edo/Riv)   | 277 | 66          | 211 (76%)| 171 (62%)     | 1.9          | 1.4       | NR       | 300–400    | NR           | Used †     | NR           | RF                  | 90 days          |
|                  |      | UI-DOAC (Apx/Dab/Edo/Riv)   | 307 | 65          | 212 (69%)| 199 (65%)     | 1.9          | 1.4       | NR       | 300–400    | NR           | Used †     | NR           | RF                  |                  |
| Yoshimoto [52]   | 2021 | UI-Edoxaban 60/30 mg OD     | 61  | 62          | 43 (70%) | 38 (62%)      | 1.7          | 1.1       | 300      | >300       | 7333         | NR         | NR           | RF                  | Unclear          |
|                  |      | UI-Rivaroxaban 15/10 mg OD  | 63  | 62          | 46 (73%) | 45 (71%)      | 1.8          | 1.2       | 298      | 7865        | NR           | NR         | RF           | Unclear            |                  |

CHA2DS2-VASc and HAS-BLED scores are the risk prediction scores of stroke and major bleeding, respectively. AF, atrial fibrillation; ACT, activated coagulation time; UFH, unfractionated heparin; ICE, intracardiac echocardiography; UI, uninterrupted; I, interrupted; DOAC, direct anticoagulant; Apx, apixaban; Dab, dabigatran; Edo, edoxaban; Riv, rivaroxaban; OD, omni die (once a day); BID, bis in die (twice a day); NR, not reported; RF, radiofrequency ablation; Cryo, cryoballoon ablation. * Median. † Numbers were unclear.
All studies reported primary efficacy (thromboembolic events) and safety (major bleeding) outcomes, while 14 and 8 studies (82% and 47%, respectively) reported minor bleeding [36–44,46,48–51] and ACE [40,42–45,48,49,52], respectively.

3.2. Risk of Bias Assessment

We evaluated all studies in five dimensions (Table S4). Concerns were noted for 14 RCTs (82%). All protocols were composed of two interventions after randomization: anticoagulant initiation and AF ablation. Since some deviations occurred before CA, outcomes were analyzed as a modified intention-to-treat population who underwent AF ablation. Some small RCTs did not mention the concealment method. However, none of the studies were classified as having a high bias risk. Therefore, we included all studies in the NMA.

3.3. Structure of the Network

Figure 2 shows the network of anticoagulant strategies used in the main analysis. We compared four strategies: UI-DOAC, I-DOAC, UI-VKA, and I-VKA, and set UI-VKA as a reference. All direct comparative studies were included, except UI-DOAC vs. I-VKA.

![Figure 2. Network of treatment comparisons for the overall primary efficacy and safety outcomes. Directly comparable treatments are linked to lines. The nodes are placed and labelled according to the treatments. The thickness of the edges is proportional to the inverse standard error of the treatment effects, aggregated over all studies, including the two respective treatments. The network includes 16 two-armed studies. UI, uninterrupted; I, interrupted; DOAC, direct oral anticoagulant; VKA, vitamin-K antagonist.](image)

3.4. NMA Results for the Primary and Secondary Outcomes

The results of the NMA for thromboembolic events, major bleeding, and the composite of primary outcomes are presented as forest plots (Figure 3a–c). I-VKA was associated with an increased risk of thromboembolic events compared to UI-VKA (OR [95% CI]: 15.77 [4.16–59.70]), whereas there was no significant difference between UI-DOAC and I-DOAC (OR: 0.97 [0.24–3.87] and OR: 1.31 [0.25–6.86]). Compared to UI-VKA, UI-DOAC significantly decreased the risk of major bleeding (OR: 0.55 [0.31–0.97]). However, I-DOAC and I-VKA did not have a significant effect (OR: 0.53 [0.22–1.23] and OR: 2.70 [0.65–11.18]). In the composite of thromboembolic events and major bleeding, UI-DOAC and I-DOAC were not inferior to UI-VKA (OR: 0.61 [0.31–1.17] and OR: 0.63 [0.26–1.54]), while I-VKA significantly increased the risk of thromboembolic events and major bleeding (OR: 8.02 [2.35–27.45]). Heterogeneity was low for primary outcomes (thromboembolic events, $I^2 = 0.0%$; major bleeding, $I^2 = 7.8%$; and the composite of primary outcomes, $I^2 = 23.4%$).
Figure 3. Forest plots for efficacy and safety of anticoagulant strategies compared with UI-VKA. (a) The efficacy of thromboembolic events (stroke, TIA, or systemic embolism); (b) the safety of major bleeding; (c) the efficacy and safety of the composite of the primary outcomes (stroke, TIA, or systemic embolism and major bleeding); (d) the safety of minor bleeding; and (e) the efficacy of asymptomatic cerebral embolism. TIA, transient ischemic attack; OR, odds ratio; CI, confidence interval; UI, uninterrupted; I, interrupted; DOAC, direct oral anticoagulant; VKA, vitamin-K antagonist.

Regarding the secondary outcomes, the NMA results for minor bleeding and ACE are presented in Figure 3d,e. Both UI-DOAC and I-DOAC carried comparable risks of minor bleeding with UI-VKA (OR: 1.11 [0.87–1.40] and OR: 1.19 [0.79–1.79]), but I-VKA significantly increased the risk (OR: 6.02 [4.19–8.66]). UI-DOAC and I-DOAC were also similar to UI-VKA for the risk of ACE (OR: 1.11 [0.67–1.83] and OR: 1.64 [0.81–3.29]). Heterogeneity was low for secondary outcomes (minor bleeding, $I^2 = 0.0\%$; and ACE, $I^2 = 22.9\%$).

Table 2 displays the P-score and SUCRA values for the primary and secondary outcomes. There were no ranking mismatches between the P-score and SUCRA. The SUCRA value of DOACs was nearly twice that of UI-VKA in the composite of the primary outcomes (UI-DOAC, 0.82; I-DOAC, 0.77; and UI-VKA, 0.40). In contrast, the secondary outcome SUCRA values were higher for UI-VKA than for DOACs; particularly, the ACE value for I-DOAC was markedly low (UI-DOAC, 0.60; I-DOAC, 0.09; and UI-VKA, 0.82).
Table 2. P-score and the SUCRA values for each strategy and outcome.

| Strategy | Thromboembolic Events | Major Bleeding | Composite of Primary Outcomes | Minor Bleeding | Asymptomatic Cerebral Embolism |
|----------|------------------------|----------------|-------------------------------|----------------|------------------------------|
|          | P-Score | SUCRA | P-Score | SUCRA | P-Score | SUCRA | P-Score | SUCRA | P-Score | SUCRA |
| UI-DOAC  | 0.72    | 0.73  | 0.81    | 0.76  | 0.82    | 0.82  | 0.62    | 0.65  | 0.64    | 0.60  |
| I-DOAC   | 0.68    | 0.70  | 0.82    | 0.85  | 0.77    | 0.77  | 0.52    | 0.49  | 0.07    | 0.09  |
| UI-VKA   | 0.60    | 0.57  | 0.33    | 0.34  | 0.41    | 0.40  | 0.87    | 0.86  | 0.79    | 0.82  |
| I-VKA    | 0.00    | 0.00  | 0.04    | 0.05  | 0.00    | 0.00  | 0.00    | 0.00  | -       | -     |

SUCRA, surface under the cumulative ranking; UI, uninterrupted; I, interrupted; DOAC, direct oral anticoagulant; VKA, vitamin-K antagonist.

Overall, the UI-DOAC strategy was favorable and the I-DOAC strategy was feasible compared with the UI-VKA strategy for the primary and secondary outcomes. However, the I-VKA strategy significantly increased the risk of thromboembolic and bleeding events compared to the UI-VKA strategy.

3.5. Sensitivity Analyses

We performed sensitivity analyses for the composite of the primary outcomes (Table S5). RE-CIRCUIT and ELIMINATE-AF were the main sources of heterogeneity [41,44]. Moreover, UI-DOAC was associated with a significant reduction in major bleeding; however, this finding was not robust because it was no longer significant when 10 studies were excluded. Overall, this analysis did not suggest that the excluded studies would affect the relative effects and rankings of the anticoagulant strategies.

3.6. Assessment of Inconsistency and Publication Bias

The inconsistency test did not suggest the presence of inconsistency in the network (Figure S1). Begg’s and Egger’s tests did not reveal significant publication bias among the included studies (Figure S2).

3.7. Subgroup Analysis

We conducted a subgroup analysis based on each anticoagulant regimen. The composite of thromboembolic and major bleeding events was analyzed and displayed in a forest plot (Figure 4) and a league table (Table S6); we also calculated the P-score and SUCRA values (Table 3). Four studies were excluded because they had no randomized regimens for each DOAC [47–49,51], and one study included both UI-DOAC arms [52]. The structure of the subgroup network is shown in Figure S3. UI-dabigatran significantly decreased the risk of the composite of the primary outcomes compared with UI-VKA (OR: 0.21 [0.08–0.55]), whereas I-VKA significantly increased the risk (OR: 8.39 [3.43–20.56]). Other anticoagulants had a comparable risk to that of UI-VKA. The P-score and SUCRA values were notably higher for UI-dabigatran and I-dabigatran than for the other anticoagulant regimens (UI-dabigatran, 0.95; and I-dabigatran, 0.82 in SUCRA).

Table 3. P-score and the SUCRA values for each strategy and composite of primary outcome.

| Strategy   | Composite of Primary Outcomes |
|------------|-------------------------------|
|            | P-Score | SUCRA |
| UI-dabigatran | 0.93    | 0.95  |
| I-dabigatran   | 0.89    | 0.82  |
| UI-apixaban    | 0.52    | 0.53  |
| I-apixaban     | 0.51    | 0.52  |
| UI-VKA        | 0.46    | 0.47  |
| UI-rivaroxaban | 0.36    | 0.41  |
| UI-edoxaban    | 0.33    | 0.30  |
| I-VKA         | 0.00    | 0.00  |

SUCRA, surface under the cumulative ranking; UI, uninterrupted; I, interrupted; VKA, vitamin-K antagonist.
with UI-DOAC compared with UI-VKA, consistent with the results of a previous meta-analysis [53–56]. Recently, worldwide RCTs have revealed that UI-DOAC may be equivalent (thrombin or factor Xa inhibitor) and a shorter half-life than warfarin. However, a recent RCTs published after 2017 have demonstrated that there were no significant differences between UI-DOAC and I-DOAC for the prevention of thromboembolic and major bleeding events [20]. Although the HRS/EHRA/ECAS/APHRS/SOLAECE 2017 expert consensus as a class I recommendation [8,9]. However, I-DOAC is also used as a periprocedural anticoagulant strategy in clinical practice owing to concerns regarding bleeding complications [20]. Although the HRS/EHRA/ECAS/APHRS/SOLAECE 2017 expert consensus statement on CA of AF classified the I-DOAC strategy as a class IIa recommendation [9]. RCTs published after 2017 have demonstrated that there were no significant differences between the UI-DOAC and I-DOAC for the prevention of thromboembolic and major bleeding complications [46–51].

Thromboembolism is the most notable complication of CA for AF. The occurrence of periprocedural stroke or TIA was reported to be 0.1–0.6% in the latest guidelines [8]. Herein, both the DOAC and UI-VKA strategies revealed comparable efficacy in preventing thromboembolic events compared with I-VKA, and there were no significant differences among them. Therefore, an uninterrupted anticoagulant strategy is usually favorable, but an interrupted DOAC administration is feasible for the prevention of thromboembolism.

The safety of anticoagulants during periprocedural management must be carefully considered. Our NMA revealed a significant reduction in major bleeding complications with UI-DOAC compared with UI-VKA, consistent with the results of a previous meta-analysis [18]. The mechanism of reduction may be related to the type of anticoagulant (thrombin or factor Xa inhibitor) and a shorter half-life than warfarin. However, a recent meta-analysis showed no significant differences between UI-DOAC and UI-VKA [19]. In the sensitivity analysis, which excluded individual studies, we could not identify the robustness of UI-DOAC for significant reduction of major bleeding without each of the

**Figure 4.** Forest plot for the composite of primary outcomes for each anticoagulant regimen. OR, odds ratio; CI, confidence interval; VKA, vitamin-K antagonist; UI, uninterrupted; I, interrupted; Dab, dabigatran; Api, apixaban; Riv, rivaroxaban; Edo, edoxaban.

4. Discussion

In this study, we compared uninterrupted or interrupted DOAC administration with uninterrupted or interrupted VKA administration as periprocedural anticoagulant strategies for patients undergoing AF ablation. The main findings were as follows: (1) the risk of thromboembolic events among the strategies was exceedingly rare (UI-DOAC: 0.20%, I-DOAC: 0.20%, and UI-VKA: 0.24%) and not significantly different within strategies, except for the I-VKA strategy (4.79%); (2) ACE occurred with an incidence of 15–21%; (3) major bleeding tended to be halved by DOAC compared with UI-VKA administration; (4) minor bleeding did not differ between DOACs and VKAs, except for I-VKA; and (5) UI-dabigatran significantly reduced the composite of thromboembolic and major bleeding events.

After the COMPARE trial [36], the UI-VKA strategy has been widely adopted as a periprocedural anticoagulant strategy for patients undergoing AF ablation. Meanwhile, there is growing evidence regarding the efficacy and safety of DOACs in patients with AF [53–56]. Recently, worldwide RCTs have revealed that UI-DOAC may be equivalent to UI-VKA [39,41,43,44]. Therefore, the latest guidelines classify the UI-DOAC strategy as a class I recommendation [8,9]. However, I-DOAC is also used as a periprocedural anticoagulant strategy in clinical practice owing to concerns regarding bleeding complications [20]. Although the HRS/EHRA/ECAS/APHRS/SOLAECE 2017 expert consensus statement on CA of AF classified the I-DOAC strategy as a class IIa recommendation [9]. RCTs published after 2017 have demonstrated that there were no significant differences between the UI-DOAC and I-DOAC for the prevention of thromboembolic and major bleeding complications [46–51].

Thromboembolism is the most notable complication of CA for AF. The occurrence of periprocedural stroke or TIA was reported to be 0.1–0.6% in the latest guidelines [8]. Herein, both the DOAC and UI-VKA strategies revealed comparable efficacy in preventing thromboembolic events compared with I-VKA, and there were no significant differences among them. Therefore, an uninterrupted anticoagulant strategy is usually favorable, but an interrupted DOAC administration is feasible for the prevention of thromboembolism.

The safety of anticoagulants during periprocedural management must be carefully considered. Our NMA revealed a significant reduction in major bleeding complications with UI-DOAC compared with UI-VKA, consistent with the results of a previous meta-analysis [18]. The mechanism of reduction may be related to the type of anticoagulant (thrombin or factor Xa inhibitor) and a shorter half-life than warfarin. However, a recent meta-analysis showed no significant differences between UI-DOAC and UI-VKA [19]. In the sensitivity analysis, which excluded individual studies, we could not identify the robustness of UI-DOAC for significant reduction of major bleeding without each of the
10 studies in Table S5b. However, the estimated ORs with both DOAC strategies tended to carry a lower risk of major bleeding; thus, they may be safer alternatives to UI-VKA.

The ACE associated with CA for AF is relatively common and reported in 0–12.5% of UI-DOAC, 15.0–35.7% of I-DOAC, and 8.7–18.6% of UI-VKA cases [57–59]. In a previous meta-analysis, UI-DOAC significantly reduced the occurrence of ACE compared to I-DOAC [60]. In our review, similar ACE incidence rates were observed (UI-DOAC, 16.0%; I-DOAC, 20.7%; and UI-VKA, 15.4%), but we were unable to identify a significant reduction with UI-DOAC. Although ACE is classified as a complication of unknown significance in the current guidelines [8], it may be associated with the risk of dementia, cognitive impairment, and future stroke [61,62]. Nakamura et al. reported ACE detected post CA on follow-up MRI disappeared in 79.8% of cases [48]. The remaining 20.2% may develop chronic infarcts due to debris dislodging, air embolism, or small thrombosis [63,64]. The significance of ACE remains unclear, but a continuous anticoagulant strategy is feasible as a periprocedural treatment for ACE prevention.

We set another network with each anticoagulant regimen as a subgroup analysis and found that UI-dabigatran could significantly reduce the composite of the primary outcomes. Since UI-dabigatran did not influence significantly for thromboembolic events in Table S6b, the reduction of major bleeding complications can lead to this result. Although the DOACs included apixaban, dabigatran, edoxaban, and rivaroxaban, dabigatran is a thrombin inhibitor, while the others are factor Xa inhibitors. Dabigatran can extend the activated thromboplastin time, activated coagulation time (ACT), and thrombin time to a greater extent than factor Xa inhibitors [8]. Recent RCTs that compared UI-DOAC and UI-VKA revealed that the total amount of unfractionated heparin (UFH) during AF ablation increased, owing to the use of factor Xa inhibitors (apixaban, 156% [40]; edoxaban, 124% [44]; and rivaroxaban, 133% [39,42]) compared with thrombin inhibitors (dabigatran, 104% [41]), and the mean ACT was lower with factor Xa inhibitors than with thrombin inhibitors (307 vs. 330 s). This previously reported finding [65] may contribute to the increased risk of major bleeding. Martin et al. reported that ACT was strongly correlated with the prothrombin time-international normalized ratio and dabigatran concentration, but not with factor Xa inhibitor concentration [66]. Moreover, only dabigatran was parallel with VKA in the UFH dose–response curves. In contrast, factor Xa inhibitors had a smaller effect on ACT prolongation in response to heparin. The target ACT at 300 s is supported by robust evidence for controlling the thromboembolic and bleeding risks, but this evidence depends on VKA and UFH management [67]. Consequently, dabigatran is the optimal periprocedural anticoagulant for ACT monitoring during AF ablation.

As DOACs have become the practical standard for periprocedural anticoagulant strategies, the management of major bleeding is more important. Idarucizumab, a specific reversal agent for dabigatran, is now available worldwide [68]. In contrast, andexanet alfa, a specific reversal agent for factor Xa inhibitors, is only available in some countries [69]. Therefore, UI-dabigatran allows an option to manage complications if emergency bleeding occurs anywhere in the world.

Although NMA can assess the relative effectiveness of different strategies, our study has limitations. A primary limitation is that this NMA was based on study-level rather than patient-level data, which would considerably weaken the comparison validity. Second, differentiations of bleeding criteria, the usage of protamine and intracardiac echocardiography (ICE), lengths of follow-up, and methods of measuring ACE with MRI may contribute to heterogeneity and potentially affect the interpretation of the results. In particular, the number of participants who underwent MRI was limited in three RCTs. Further studies are needed to determine the significance of the optimal anticoagulant strategy for ACE. Additionally, the usage of protamine after the ablation procedure, and ICE during transseptal puncture, can prevent bleeding events. However, there were few studies to report those applications, and this can influence bleeding outcomes. Since four studies that investigated DOACs were not randomized into individual anticoagulants, a pooled comparison of a specific regimen in NMA could not be performed, and this weakened the interpretation.
Moreover, some regimens lacked data and were dependent on one study because of the limited number of RCTs. As RCTs of I-DOAC were mainly conducted in Japan, their results may involve regional bias.

5. Conclusions

In patients undergoing AF ablation, both DOAC strategies were associated with a lower incidence of major bleeding and had a similar effect on the prevention of thromboembolic events and minor bleeding compared with the UI-VKA strategy, whereas the I-VKA strategy should generally be avoided. Continuous DOAC and VKA administration was associated with a lower incidence of ACE. Therefore, UI-DOAC is the preferable alternative to UI-VKA. Although further data on the outcomes of patients receiving UI-dabigatran are needed for definitive conclusions, our results support the use of UI-dabigatran as the optimal periprocedural anticoagulant for ACT monitoring during AF ablation.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11071872/s1, Figure S1: Inconsistency analysis; Figure S2: Comparison adjusted funnel plot; Figure S3: Network of anticoagulant comparisons for the composite of primary outcomes; Table S1: PRISMA network meta-analysis checklist; Table S2: PICOS format and detailed search code; Table S3: Efficacy and safety outcomes in the included studies; Table S4: Assessment of bias in the randomized clinical trials; Table S5: Sensitivity analysis; Table S6: Summary estimates for outcomes with each anticoagulant regimen from network meta-analysis.

Author Contributions: Conceptualization, T.K.; methodology, T.Y.; software, T.K.; validation, H.Y. and T.I. (Tomoaki Ishigami); formal analysis, T.K.; investigation, S.I., M.A. and S.A.; resources, T.K.; data curation, M.K. and T.Y.; writing—original draft preparation, T.K.; writing—review and editing, M.K., T.Y., H.Y. and T.I. (Tomoaki Ishigami); visualization, T.K.; supervision, T.I. (Toshiyuki Ishikawa); project administration, T.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data are incorporated into the article and its online supplementary material.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Benjamin, E.J.; Muntner, P.; Alonso, A.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Das, S.R.; et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation* 2019, 139, e56–e528. [CrossRef] [PubMed]
2. Arbelo, E.; Brugada, J.; Hindricks, G.; Maggioni, A.; Tavazzi, L.; Vardas, P.; Anselme, F.; Inama, G.; Jais, P.; Kalarus, Z.; et al. ESC-EURObservational Research Programme: The Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. *Europace* 2012, 14, 1094–1103. [CrossRef] [PubMed]
3. Reddy, V.Y.; Dukkipati, S.R.; Neuzil, P.; Natale, A.; Albenque, J.P.; Kautzner, J.; Shah, D.; Michaud, G.; Wharton, M.; Harari, D.; et al. Randomized, Controlled Trial of the Safety and Effectiveness of a Contact Force-Sensing Irrigated Catheter for Ablation of Paroxysmal Atrial Fibrillation: Results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) Study. *Circulation* 2015, 132, 907–915. [CrossRef]
4. Stabile, G.; Scaglione, M.; del Greco, M.; De Ponti, R.; Bongiorni, M.G.; Zoppo, F.; Soldati, E.; Marazzi, R.; Marini, M.; Gaia, F.; et al. Reduced fluoroscopy exposure during ablation of atrial fibrillation using a novel electroanatomical navigation system: A multicentre experience. *Europace* 2012, 14, 60–65. [CrossRef] [PubMed]
5. McLellan, A.J.; Ling, L.H.; Azzopardi, S.; Lee, G.A.; Lee, G.; Kumar, S.; Wong, M.C.; Walters, T.E.; Lee, J.M.; Looi, K.L.; et al. A minimal or maximal ablation strategy to achieve pulmonary vein isolation for paroxysmal atrial fibrillation: A prospective multi-centre randomized controlled trial (the Minimax study). *Eur. Heart J.* 2015, 36, 1812–1821. [CrossRef] [PubMed]
6. Verma, A.; Jiang, C.Y.; Betts, T.R.; Chen, J.; Deisenhofer, I.; Mantovan, R.; Macle, L.; Morillo, C.A.; Havercamp, W.; Weerasooriya, R.; et al. Approaches to catheter ablation for persistent atrial fibrillation. *N. Engl. J. Med.* 2015, 372, 1812–1822. [CrossRef]
7. Nery, P.B.; Belliveau, D.; Nair, G.M.; Bernick, J.; Redpath, C.J.; Szczotka, A.; Sadek, M.M.; Green, M.S.; Wells, G.; Birnie, D.H. Relationship Between Pulmonary Vein Reconnection and Atrial Fibrillation Recurrence: A Systematic Review and Meta-Analysis. JACC Clin. Electrophysiol. 2016, 2, 474–483. [CrossRef]

8. Hindricks, G.; Potpara, T.; Dagres, N.; Arbelo, E.; Bax, J.J.; Blomström-Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.A.; Dilaveris, P.E.; et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021, 42, 373–498. [CrossRef]

9. Calkins, H.; Hindricks, G.; Cappato, R.; Kim, Y.H.; Saad, E.B.; Aguinaldo, L.; Akar, J.G.; Bhatt, D.L.; Brugada, J.; Camm, J.; et al. 2017 HRS/ESC/AHA/APHRS/SOLACE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017, 14, e275–e444. [CrossRef]

10. Packer, D.L.; Mark, D.B.; Robb, R.A.; Monahan, K.H.; Bahnson, T.D.; Poole, J.E.; Noseworthy, P.A.; Rosenberg, Y.D.; Jeffries, N.; Mitchell, L.B.; et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients with Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA 2019, 321, 1261–1274. [CrossRef]

11. Ruff, C.T.; Garg, R.;发起; et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014, 383, 955–962. [CrossRef]

12. Basiouny, M.; Saibah, W.; Rickard, J.; Shao, M.; Sey, A.; Diab, M.; Martin, D.O.; Hussein, A.; Khoury, M.; Abi-Saleh, B.; et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ. Arrhythm. Electrophysiol. 2013, 6, 460–466. [CrossRef]

13. Bin Abdulhak, A.A.; Khan, A.R.; Teyjejh, I.M.; Spertus, J.A.; Sanders, S.U.; Steigerwald, K.E.; Garbati, M.A.; Bahmaid, R.A.; Wimmer, A.P. Safety and efficacy of interrupted dabigatran for per-procedural anticoagulation in catheter ablation of atrial fibrillation: A systematic review and meta-analysis. Europace 2013, 15, 1412–1420. [CrossRef] [PubMed]

14. Hohnloser, S.H.; Camm, A.J. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: A meta-analysis of the literature. Europace 2013, 15, 1407–1411. [CrossRef] [PubMed]

15. Providencio, R.; Marijon, E.; Albenque, J.P.; Combes, S.; Combes, N.; Jourda, F.; Hicche, H.; Morais, J.; Boveda, S. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace 2014, 16, 1137–1144. [CrossRef] [PubMed]

16. Armbruster, H.L.; Lindsay, J.P.; Moranville, M.P.; Habibi, M.; Khurram, I.M.; Spragg, D.D.; Berger, R.D.; Calkins, H.; Marine, J.E. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Ann. Pharmac. 2015, 49, 278–284. [CrossRef]

17. Rahman, H.; Khan, S.U.; DePersis, M.; Hammad, T.; Nasir, F.; Kaluski, E. Meta-analysis of safety and efficacy of oral anticoagulants in patients requiring catheter ablation for atrial fibrillation. Cardiovasc. Revasc. Med. 2019, 20, 147–152. [CrossRef]

18. Zhao, Y.; Lu, Y.; Qin, Y. A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation. Int. J. Cardiol. 2018, 270, 167–171. [CrossRef] [PubMed]

19. Brockmeyer, M.; Lin, Y.; Parco, C.; Karathanos, A.; Krieger, T.; Schulze, V.; Heinen, Y.; Bejinariu, A.; Müller, P.; Makimoto, H.; et al. Uninterrupted anticoagulation during cardiac ablation for atrial fibrillation: No difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials. Acta Cardiol. 2021, 76, 288–295. [CrossRef] [PubMed]

20. Bejinariu, A.G.; Makimoto, H.; Wakili, R.; Mathew, S.; Kosiuuk, J.; Linz, D.; Steinfurt, J.; Dechering, D.G.; Meyer, C.; Veltmann, C.; et al. One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey. Cardiology 2020, 145, 676–681. [CrossRef]

21. Ottóffy, M.; Mátrai, P.; Farkas, N.; Hegyi, P.; Czopf, L.; Mátra, K.; Garami, A.; Baláskó, M.; Pótoné-Oláh, E.; Mikó, A.; et al. Uninterrupted or Minimally Interrupted Direct Oral Anticoagulant Therapy is a Safe Alternative to Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation: An Updated Meta-Analysis. J. Clin. Med. 2020, 9, 3073. [CrossRef] [PubMed]

22. van Vugt, S.; Westra, S.W.; Vollebergh, R.; Hannink, G.; Nakamura, R.; de Asmundis, C.; Cherchiera, G.B.; Navarese, E.P.; Brouwer, M.A. Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation. Europace 2021, 23, 1961–1969. [CrossRef] [PubMed]

23. Rouse, B.; Chaimani, A.; Li, T. Network meta-analysis: An introduction for clinicians. Intern. Emerg. Med. 2017, 12, 103–111. [CrossRef] [PubMed]

24. Hutton, B.; Salanti, G.; Caldwell, D.M.; Chaimani, A.; Schmid, C.H.; Cameron, C.; Ioannidis, J.P.; Straus, S.; Thorlund, K.; Jansen, J.P.; et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann. Intern. Med. 2015, 162, 777–784. [CrossRef] [PubMed]

25. Mehran, R.; Rao, S.V.; Bhatt, D.L.; Gibson, C.M.; Caixeta, A.; Eikelboom, J.; Kaul, S.; Wiviott, S.D.; Menon, V.; Nikolsky, E.; et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011, 123, 2736–2747. [CrossRef] [PubMed]

26. Schulman, S.; Kearon, C.; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. J. Thromb. Haemost. 2005, 3, 692–694. [CrossRef] [PubMed]
27. Sterne, J.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019, 366, 14898. [CrossRef] [PubMed]

28. Rücker, G.; Schwarzer, G. Resolve conflicting rankings of outcomes in network meta-analysis: Partial ordering of treatments. Res. Synth. Methods 2017, 8, 526–536. [CrossRef]

29. Rücker, G.; Schwarzer, G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med. Res. Methodol. 2015, 15, 58. [CrossRef]

30. Krahn, U.; Binder, H.; König, J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med. Res. Methodol. 2013, 13, 35. [CrossRef]

31. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [CrossRef] [PubMed]

32. Veroniki, A.A.; Vasiliadis, H.S.; Higgins, J.P.; Salanti, G. Evaluation of inconsistency in networks of interventions. Int. J. Epidemiol. 2013, 42, 332–345. [CrossRef] [PubMed]

33. White, I.R.; Barrett, J.K.; Jackson, D.; Higgins, J.P. Consistency and inconsistency in network meta-analysis: Model estimation using multivariate meta-regression. Res. Synth. Methods 2012, 3, 111–125. [CrossRef] [PubMed]

34. Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [CrossRef] [PubMed]

35. Begg, C.B.; Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50, 1088–1101. [CrossRef]

36. Di Biase, L.; Burkhardt, J.D.; Santangeli, P.; Mohanty, P.; Sanchez, J.E.; Horton, R.; Gallinghouse, G.J.; Themistoclakis, S.; Rossillo, A.; Lakkreedi, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: Results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014, 129, 2638–2644. [CrossRef]

37. Nin, T.; Sairaku, A.; Yoshida, Y.; Kamiya, H.; Tatematsu, Y.; Nanasato, M.; Inden, Y.; Hirayama, H.; Murohara, T. A randomized controlled trial of dabigatran versus warfarin for periblation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin. Electrophysiol. 2013, 36, 172–179. [CrossRef]

38. Nogami, A.; Harada, T.; Sekiguchi, Y.; Otani, R.; Yoshida, Y.; Yoshida, K.; Nakano, Y.; Nuruki, N.; Nakahara, S.; Goya, M.; et al. Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial. JAMA Netw. Open 2019, 2, e191994. [CrossRef]

39. Cappato, R.; Marchlinski, F.E.; Hohnloser, S.H.; Naccarelli, G.V.; Xiang, J.; Wilber, D.J.; Ma, C.S.; Hess, S.; Wells, D.S.; Juang, G.; et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur. Heart J. 2015, 36, 1805–1811. [CrossRef]

40. Kuwahara, T.; Abe, M.; Yamaki, M.; Fujieda, H.; Abe, Y.; Hashimoto, K.; Ishiba, M.; Sakai, H.; Hishikari, K.; Takigawa, M.; et al. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study. J. Cardiovasc. Electrophysiol. 2016, 27, 549–554. [CrossRef]

41. Calkins, H.; Willems, S.; Gerstenfeld, E.P.; Verma, A.; Schilling, R.; Hohnloser, S.H.; Okumura, K.; Serota, H.; Nordaby, M.; Guiver, K.; et al. Uninterrupted Dabigatran versus Warfarin in Ablation for Atrial Fibrillation. N. Engl. J. Med. 2017, 376, 1627–1636. [CrossRef] [PubMed]

42. Kimura, T.; Kashimura, S.; Nishiyama, T.; Katsumata, Y.; Inagawa, K.; Ikegami, Y.; Nishiyama, N.; Fukumoto, K.; Tanimoto, Y.; Aizawa, Y.; et al. Asymptomatic Cerebral Infarction During Catheter Ablation for Atrial Fibrillation: Comparing Uninterrupted Rivaroxaban and Warfarin (ASCERTAIN). JACC Clin. Electrophysiol. 2018, 4, 1598–1609. [CrossRef]

43. Kirchhof, P.; Haesler, K.G.; Blank, B.; De Bono, J.; Callans, D.; Elvan, A.; Fetsch, T.; Van Gelder, I.C.; Gentlesk, P.; Grimaldi, M.; et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur. Heart J. 2018, 39, 2942–2955. [CrossRef] [PubMed]

44. Hohnloser, S.H.; Camm, J.; Cappato, R.; Diener, H.C.; Heidbüchel, H.; Mont, L.; Morillo, C.A.; Abozguia, K.; Grimaldi, M.; Rauer, H.; et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: The ELIMINATE-AF trial. Eur. Heart J. 2019, 40, 3013–3021. [CrossRef]

45. Yoshimura, A.; Iiri, Y.; Ichiki, H.; Oketani, N.; Okui, H.; Maenosono, R.; Namino, F.; Miyata, M.; Ohishi, M. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. J. Cardiol. 2017, 69, 228–235. [CrossRef] [PubMed]

46. Reynolds, M.R.; Allison, J.S.; Natale, A.; Weisberg, I.L.; Ellenbogen, K.A.; Richards, M.; Hsieh, W.H.; Sutherland, J.; Cannon, C.P. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial. JACC Clin. Electrophysiol. 2018, 4, 580–588. [CrossRef]

47. Yu, H.T.; Shim, J.; Park, J.; Kim, T.H.; Uhm, J.S.; Kim, J.Y.; Joung, B.; Lee, M.H.; Kim, Y.H.; Pak, H.N. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. Eur. Heart J. 2019, 40, 1531–1537. [CrossRef]
48. Nakamura, K.; Naito, S.; Sasaki, T.; Take, Y.; Minami, K.; Kitagawa, Y.; Motoda, H.; Inoue, M.; Otsuka, Y.; Niijima, K.; et al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: A prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. *Europace* **2019**, *21*, 259–267. [CrossRef] [PubMed]

49. Nagao, T.; Suzuki, H.; Matsunaga, S.; Nishikawa, Y.; Harada, K.; Mamiya, K.; Shinoda, N.; Harada, K.; Kato, M.; Marui, N.; et al. Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: Uninterrupted vs. interrupted by one dose strategy. *Europace* **2019**, *21*, 590–597. [CrossRef] [PubMed]

50. Ando, M.; Inden, Y.; Yoshida, Y.; Sairaku, A.; Yanagisawa, S.; Suzuki, H.; Watanabe, R.; Takenaka, M.; Maeda, M.; Murohara, T. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: A randomized controlled study. *Heart Vessels* **2019**, *34*, 1533–1541. [CrossRef]

51. Yamaji, H.; Murakami, T.; Hina, K.; Higashiyama, S.; Kawamura, H.; Murakami, M.; Kamikawa, S.; Hirohata, S.; Kusachi, S. Activated clotting time monitoring. *J. Cardiowasc. Electrophysiol.* **2019**, *30*, 2823–2833. [CrossRef] [PubMed]

52. Yoshimoto, I.; Iriki, Y.; Oketani, N.; Okui, H.; Ichiki, H.; Maenosono, R.; Namino, F.; Miyata, M.; Ohishi, M. A randomized comparison of two direct oral anticoagulants for patients undergoing cardiac ablation with a contemporary warfarin control arm. *J. Inter. Card. Electrophysiol.* **2021**, *60*, 375–385. [CrossRef] [PubMed]

53. Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P.A.; Themeles, E.; Varrone, J.; et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N. Engl. J. Med.* **2009**, *361*, 1139–1151. [CrossRef] [PubMed]

54. Patel, M.R.; Mahaffey, K.W.; Garg, J.; Fan, G.; Singer, D.E.; Hacke, W.; Breithardt, G.; Halperin, J.L.; Hankey, G.J.; Piccirini, J.P.; et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N. Engl. J. Med.* **2011**, *365*, 883–891. [CrossRef] [PubMed]

55. Granger, C.B.; Alexander, J.H.; McMurray, J.J.; Lopes, R.D.; Hylek, E.M.; Hanna, M.; Al-Khalidi, H.R.; Ansell, J.; Atar, D.; Avezum, A.; et al. Apixaban versus warfarin in patients with atrial fibrillation. *N. Engl. J. Med.* **2011**, *365*, 981–992. [CrossRef] [PubMed]

56. Giugliano, R.P.; Ruff, C.T.; Braunwald, E.; Murphy, S.A.; Vlietvoet, S.D.; Halperin, J.L.; Waldo, A.L.; Ezekowitz, M.D.; Weitz, J.I.; Spinari, J.; et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N. Engl. J. Med.* **2013**, *369*, 2093–2104. [CrossRef]

57. Müller, P.; Halbfass, P.; Szöllösi, A.; Dietrich, J.W.; Fochler, F.; Nentwich, K.; Roos, M.; Krug, J.; Schmitt, R.; Mügge, A.; et al. Impact of periprocedural anticoagulation strategy on the incidence of new-onset silent cerebral events after radiofrequency catheter ablation of atrial fibrillation. *J. Inter. Card. Electrophysiol.* **2016**, *46*, 203–211. [CrossRef]

58. Di Biase, L.; Lakkireddy, D.; Trivedi, C.; Denike, T.; Martinek, M.; Mohanthy, S.; Mohanthy, P.; Prakash, S.; Bai, R.; Reddy, M.; et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study. *Heart Rhythm* **2015**, *12*, 1162–1168. [CrossRef]

59. Nakamura, K.; Naito, S.; Sasaki, T.; Minami, K.; Take, Y.; Goto, E.; Shimizu, S.; Yamaguchi, Y.; Suzuki, N.; Yano, T.; et al. Silent Cerebral Ischemic Lesions After Catheter Ablation of Atrial Fibrillation in Patients on 5 Types of Periprocedural Oral Anticoagulation—Predictors of Diffusion-Weighted Imaging-Positive Lesions and Follow-up Magnetic Resonance Imaging. *Circ. J.* **2016**, *80*, 870–877. [CrossRef]

60. Mao, Y.J.; Wang, H.; Huang, P.F. Peri-procedural novel oral anticoagulants dosing strategy during atrial fibrillation ablation: A meta-analysis. *Pacing Clin. Electrophysiol.* **2020**, *43*, 1104–1114. [CrossRef]

61. Vermeer, S.E.; Prins, N.D.; den Heijer, T.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M. Silent brain infarcts and the risk of dementia and cognitive decline. *N. Engl. J. Med.* **2003**, *348*, 1215–1222. [CrossRef] [PubMed]

62. Gupta, A.; Giambone, A.E.; Gialdini, G.; Finn, C.; Delgado, D.; Gutierrez, J.; Wright, C.; Beiser, A.S.; Seshadri, S.; Pandya, A.; et al. Silent Brain Infarction and Risk of Future Stroke: A Systematic Review and Meta-Analysis. *Stroke* **2016**, *47*, 719–725. [CrossRef] [PubMed]

63. Haines, D.E.; Stewart, M.T.; Barka, N.D.; Kirchhof, N.; Lentz, L.R.; Reinking, N.M.; Urban, J.F.; Halimi, F.; Deneke, T.; Kanal, E. Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants. *Europace* **2019**, *21*, 767–775. [CrossRef] [PubMed]

64. Takami, M.; Lehmann, H.I.; Parker, K.D.; Welker, K.M.; Johnson, S.B.; Packer, D.L. Effect of Left Atrial Ablation Process and Strategy on Microemboli Formation During Irrigated Radiofrequency Catheter Ablation in An In Vivo Model. *Circ. Arrhythmia Electrophysiol.* **2016**, *9*, e003226. [CrossRef] [PubMed]

65. Maury, P.; Belaid, S.; Ribes, A.; Voglimumaci-Stephanopoli, Q.; Mondoly, P.; Blaye, M.; Mandel, F.; Monteil, B.; Carrière, D.; Galinier, M.; et al. Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs. *J. Arrhythmia* **2020**, *36*, 644–651. [CrossRef]

66. Martin, A.C.; Kyheng, M.; Foisaud, V.; Duhamel, A.; Marjion, E.; Susen, S.; Godier, A. Activated Clotting Time Monitoring during Atrial Fibrillation Catheter Ablation: Does the Anticoagulant Matter? *J. Clin. Med.* **2020**, *9*, 350. [CrossRef] [PubMed]
67. Martin, A.C.; Godier, A.; Narayanan, K.; Smadja, D.M.; Marijon, E. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence. *Circulation* **2018**, *138*, 627–633. [CrossRef]

68. Pollack, C.V.; Reilly, P.A., Jr.; Eikelboom, J.; Glund, S.; Verhamme, P.; Bernstein, R.A.; Dubiel, R.; Huisman, M.V.; Hylek, E.M.; Kamphuisen, P.W.; et al. Idarucizumab for Dabigatran Reversal. *N. Engl. J. Med.* **2015**, *373*, 511–520. [CrossRef] [PubMed]

69. Connolly, S.J.; Milling, T.J., Jr.; Eikelboom, J.W.; Gibson, C.M.; Curnutte, J.T.; Gold, A.; Bronson, M.D.; Lu, G.; Conley, P.B.; Verhamme, P.; et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. *N. Engl. J. Med.* **2016**, *375*, 1131–1141. [CrossRef]